Target Price | $66.30 |
Price | $47.82 |
Potential |
38.64%
register free of charge
|
Number of Estimates | 19 |
19 Analysts have issued a price target Avidity Biosciences Inc 2026 .
The average Avidity Biosciences Inc target price is $66.30.
This is
38.64%
register free of charge
$100.80
110.79%
register free of charge
$50.50
5.60%
register free of charge
|
|
A rating was issued by 22 analysts: 21 Analysts recommend Avidity Biosciences Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Avidity Biosciences Inc stock has an average upside potential 2026 of
38.64%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 10.90 | 9.11 |
14.02% | 16.39% | |
EBITDA Margin | -3,451.01% | -6,137.53% |
41.29% | 77.85% | |
Net Margin | -2,956.88% | -6,016.56% |
33.20% | 103.48% |
17 Analysts have issued a sales forecast Avidity Biosciences Inc 2025 . The average Avidity Biosciences Inc sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Avidity Biosciences Inc EBITDA forecast 2025. The average Avidity Biosciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Avidity Biosciences Inc Analysts have issued a net profit forecast 2025. The average Avidity Biosciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.89 | -4.54 |
0.69% | 57.09% | |
P/E | negative | |
EV/Sales | 545.27 |
18 Analysts have issued a Avidity Biosciences Inc forecast for earnings per share. The average Avidity Biosciences Inc EPS is
This results in the following potential growth metrics and future valuations:
Avidity Biosciences Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
Wolfe Research |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
Raymond James |
Locked
➜
Locked
|
Locked | Jun 11 2025 |
Analyst Rating | Date |
---|---|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 08 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Aug 08 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 08 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jul 10 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jun 27 2025 |
Locked
Wolfe Research:
Locked
➜
Locked
|
Jun 17 2025 |
Locked
Raymond James:
Locked
➜
Locked
|
Jun 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.